[Alzheimer's Drug Discovery Foundation](https://www.alzdiscovery.org)

January 12, 2026 (Invited Full Proposal) | September 14, 2026 (Letter of Intent)

Up to $5,000,000 per award; multi-year projects supported; direct costs only.

Supports IND-enabling studies and early-phase clinical trials for novel drugs and devices targeting Alzheimer’s disease and related dementias.

Anti-amyloid and cholinesterase inhibitor proposals are not eligible.

--- ## Description This opportunity funds investigational new drug (IND)-enabling studies and early-phase clinical trials for promising pharmacological interventions and devices aimed at Alzheimer’s disease and related dementias. The focus is on projects targeting diverse drug mechanisms and novel therapeutic modalities relevant to the biology of aging and dementia, including small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Projects must provide a clear rationale, compelling biological evidence, and robust preliminary data. Collaboration across organizations is encouraged, and all funded clinical trials must be registered on ClinicalTrials.gov. --- ## Due Dates - January 12, 2026: Invited Full Proposal deadline (must be received by 5:00 pm ET) - September 14, 2026: Letter of Intent deadline (must be received by 5:00 pm ET) --- ## Funding Amount - Maximum award: Up to $5,000,000 per project, based on stage and scope of research. - Duration: Multi-year funding is typical. - Only direct costs are allowed; co-funding is encouraged for larger studies. - Payment is milestone-based and negotiable. --- ## Eligibility - Open to researchers and clinicians worldwide. - Eligible organizations: - Academic medical centers, universities, and nonprofits. - Biotechnology companies, including startups. - Industry partnerships are encouraged. - Funding is provided as mission-related investments, requiring return on investment based on scientific and/or business milestones. - Proposals focused on anti-amyloid mechanisms or cholinesterase inhibitors are not eligible. --- ## Application Process 1. **Letter of Intent (LOI):** - Submit via the [ADDF Funding Portal](https://addf.fluxx.io/). - Brief descriptions required: scientific rationale, specific aims, key supporting data. - Notification of invitation for full proposal typically within 2–3 weeks of LOI deadline. 2. **Full Proposal (by invitation only):** - Submit through the same portal. - Requires detailed project narrative, budget, biosketches, and (for biotech companies) a business packet. - Applications are reviewed by scientific and business review boards. - Notification of funding decision typically within 3–4 months of full proposal deadline. 3. **Key Restrictions:** - One LOI and one invited full proposal per applicant per cycle. - Academic institutions may have multiple applicants for different projects. - Biotechnology companies are limited to one LOI and one full proposal per cycle. - Effective 2026, full proposals must be submitted in the same cycle as their LOI. --- ## Additional Information - Only direct costs are allowed; indirect costs, capital equipment, and overhead are not funded. - All clinical trials funded must be registered on [ClinicalTrials.gov](https://register.clinicaltrials.gov/). - ADDF prioritizes projects with novel intellectual property or clear strategies for developing new IP. - Collaboration with external partners and CROs is encouraged. --- ## External Links - [Funding Opportunity Details](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-rfp) - [Application Instructions](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/application-instructions) - [Funding Policies](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/policies) - [ADDF Funding Portal (Apply)](https://addf.fluxx.io/) --- ## Contact Information | Contact | Email | Phone | Web Form | |----------------------------------|------------------------------|---------------|--------------------------------------------------------------------------| | Grants & Mission-Related Investments Team | grants@alzdiscovery.org | 212.901.8000 | [Contact Us](https://www.alzdiscovery.org/contact-us) |

Drug Development RFP

Sign in to see full grant listing